Global Long-acting Anti-HIV Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Long-acting Anti-HIV Drugs market size was valued at US$ 310 million in 2025 and is forecast to a readjusted size of US$ 817 million by 2032 with a CAGR of 14.8% during review period.
Long-acting anti-HIV drugs are antiretroviral products formulated with extended-release technologies to maintain therapeutic drug exposure over prolonged intervals, enabling HIV treatment (ART) or prevention (PrEP) to be delivered weekly, monthly, or even less frequently rather than requiring daily oral dosing. They are designed to address real-world adherence and stigma-related barriers: durable viral suppression depends on consistent medication intake, yet missed doses, treatment fatigue, irregular routines, and privacy concerns can undermine outcomes and increase transmission risk; long-acting dosing reduces pill burden and the day-to-day “reminder” of therapy, improving continuity of care and quality of life while expanding prevention options for people who struggle with daily PrEP. Historically, HIV care progressed from early multi-pill oral regimens toward potent combination therapies with better safety and resistance profiles, after which innovation increasingly focused on delivery and adherence; advances in formulation science and drug-delivery platforms enabled extended-release approaches such as intramuscular or subcutaneous injections and implants, using technologies like nanosuspensions, microspheres, lipid/polymer carriers, or controlled-release matrices to provide predictable exposure over time. The upstream supply chain typically spans active pharmaceutical ingredients and key intermediates (specialty chemicals, chiral reagents, solvents, catalysts), formulation excipients (biodegradable polymers such as PLGA, lipids, surfactants, stabilizers, and release-controlling matrices), and sterile delivery/packaging inputs (prefilled syringes and needle components, rubber stoppers and seals, sterile filters, glass or high-barrier polymer containers), along with critical manufacturing and quality-control “components” (single-use fluid paths, pumps/valves, isolator and HEPA filtration elements, in-line sensors for particle size/viscosity, cold-chain temperature indicators). Because long-acting products place tighter constraints on sterility assurance, particle-size distribution, release-profile consistency, and storage stability, upstream material quality systems and regulatory-grade traceability are often decisive for batch release and reliable commercial supply.In 2025, global production capacity for long-acting anti-HIV drugs reached 150,000 doses, while sales totaled 130,200 doses. The average selling price was approximately USD 2,312 per dose, and gross margins across manufacturers were in the range of 60%–70%.
In the current market landscape, long-acting anti-HIV therapy and prevention are moving from “clinically feasible” to “real-world deployable,” with commercialization increasingly shaped by adherence outcomes, service accessibility, and reimbursement pathways rather than efficacy alone. In practice, adoption tends to concentrate in populations where daily dosing is challenging due to unstable routines, pill fatigue, or privacy concerns, while broader rollout depends heavily on care delivery readiness—standardized visit scheduling, repeatable injection workflows, cold-chain and inventory control, and robust management of adverse events and the so-called pharmacokinetic “tail.” As clinicians and patients gain experience, conversations are shifting from whether long-acting options work to who benefits most, how to switch safely, and how to sustain therapy over time, with stronger integration into sexual health clinics, community programs, and public health initiatives—making “drug plus service” the de facto product.
Looking ahead, innovation is likely to track toward longer dosing intervals, more stable exposure, higher resistance barriers, simpler administration, and a better patient experience, supported by multiple delivery platforms in parallel. On the regimen side, development momentum favors combinations and strategies that maintain a strong barrier to resistance and reduce vulnerability during transitions or missed visits. On the formulation side, continued optimization of nanosuspensions, microspheres, lipid/polymer carriers, and implants aims to improve injection volume, local tolerability, release predictability, and storage/transport stability. On the system side, care models will diversify beyond conventional clinic injections, pairing long-acting dosing with telehealth follow-up, community-based administration, mobile care teams, and digital tools for appointment and adherence management, creating delivery pathways that better match local resource constraints. In prevention settings, long-acting options may enable more sustainable coverage for higher-risk groups by reducing discontinuation and improving continuity of protection.
The market is propelled and constrained by forces that operate simultaneously. Key drivers include public health priorities around sustained suppression and sustained prevention, patient demand for improved quality of life and discretion, and payer interest in avoiding lapses that lead to complications and onward transmission; on the industry side, maturation of formulation platforms, sterile manufacturing capabilities, and increasingly standardized service delivery all support uptake. Major barriers include access limitations inherent to facility-based administration, operational burdens from cold-chain and inventory requirements, management of injection-site reactions and long-term tolerability, and the resistance and transmission risks associated with interruption during the drug “tail,” which necessitate disciplined screening, follow-up, and contingency plans. Regional variation in regulation, procurement, and reimbursement can further slow penetration, while stigma, information gaps, and suboptimal service experiences may undermine persistence. As a result, competitive advantage will increasingly hinge not only on the molecule, but on end-to-end capabilities across screening, dosing, follow-up, supply assurance, and risk management.
This report is a detailed and comprehensive analysis for global Long-acting Anti-HIV Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Long-acting Anti-HIV Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting Anti-HIV Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting Anti-HIV Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting Anti-HIV Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-acting Anti-HIV Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-acting Anti-HIV Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ViiV Healthcare, Janssen Pharmaceuticals, Gilead Sciences, Theratechnologies, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Long-acting Anti-HIV Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Long-acting Anti-HIV Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-acting Anti-HIV Drugs, with price, sales quantity, revenue, and global market share of Long-acting Anti-HIV Drugs from 2021 to 2026.
Chapter 3, the Long-acting Anti-HIV Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-acting Anti-HIV Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Long-acting Anti-HIV Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting Anti-HIV Drugs.
Chapter 14 and 15, to describe Long-acting Anti-HIV Drugs sales channel, distributors, customers, research findings and conclusion.
Long-acting anti-HIV drugs are antiretroviral products formulated with extended-release technologies to maintain therapeutic drug exposure over prolonged intervals, enabling HIV treatment (ART) or prevention (PrEP) to be delivered weekly, monthly, or even less frequently rather than requiring daily oral dosing. They are designed to address real-world adherence and stigma-related barriers: durable viral suppression depends on consistent medication intake, yet missed doses, treatment fatigue, irregular routines, and privacy concerns can undermine outcomes and increase transmission risk; long-acting dosing reduces pill burden and the day-to-day “reminder” of therapy, improving continuity of care and quality of life while expanding prevention options for people who struggle with daily PrEP. Historically, HIV care progressed from early multi-pill oral regimens toward potent combination therapies with better safety and resistance profiles, after which innovation increasingly focused on delivery and adherence; advances in formulation science and drug-delivery platforms enabled extended-release approaches such as intramuscular or subcutaneous injections and implants, using technologies like nanosuspensions, microspheres, lipid/polymer carriers, or controlled-release matrices to provide predictable exposure over time. The upstream supply chain typically spans active pharmaceutical ingredients and key intermediates (specialty chemicals, chiral reagents, solvents, catalysts), formulation excipients (biodegradable polymers such as PLGA, lipids, surfactants, stabilizers, and release-controlling matrices), and sterile delivery/packaging inputs (prefilled syringes and needle components, rubber stoppers and seals, sterile filters, glass or high-barrier polymer containers), along with critical manufacturing and quality-control “components” (single-use fluid paths, pumps/valves, isolator and HEPA filtration elements, in-line sensors for particle size/viscosity, cold-chain temperature indicators). Because long-acting products place tighter constraints on sterility assurance, particle-size distribution, release-profile consistency, and storage stability, upstream material quality systems and regulatory-grade traceability are often decisive for batch release and reliable commercial supply.In 2025, global production capacity for long-acting anti-HIV drugs reached 150,000 doses, while sales totaled 130,200 doses. The average selling price was approximately USD 2,312 per dose, and gross margins across manufacturers were in the range of 60%–70%.
In the current market landscape, long-acting anti-HIV therapy and prevention are moving from “clinically feasible” to “real-world deployable,” with commercialization increasingly shaped by adherence outcomes, service accessibility, and reimbursement pathways rather than efficacy alone. In practice, adoption tends to concentrate in populations where daily dosing is challenging due to unstable routines, pill fatigue, or privacy concerns, while broader rollout depends heavily on care delivery readiness—standardized visit scheduling, repeatable injection workflows, cold-chain and inventory control, and robust management of adverse events and the so-called pharmacokinetic “tail.” As clinicians and patients gain experience, conversations are shifting from whether long-acting options work to who benefits most, how to switch safely, and how to sustain therapy over time, with stronger integration into sexual health clinics, community programs, and public health initiatives—making “drug plus service” the de facto product.
Looking ahead, innovation is likely to track toward longer dosing intervals, more stable exposure, higher resistance barriers, simpler administration, and a better patient experience, supported by multiple delivery platforms in parallel. On the regimen side, development momentum favors combinations and strategies that maintain a strong barrier to resistance and reduce vulnerability during transitions or missed visits. On the formulation side, continued optimization of nanosuspensions, microspheres, lipid/polymer carriers, and implants aims to improve injection volume, local tolerability, release predictability, and storage/transport stability. On the system side, care models will diversify beyond conventional clinic injections, pairing long-acting dosing with telehealth follow-up, community-based administration, mobile care teams, and digital tools for appointment and adherence management, creating delivery pathways that better match local resource constraints. In prevention settings, long-acting options may enable more sustainable coverage for higher-risk groups by reducing discontinuation and improving continuity of protection.
The market is propelled and constrained by forces that operate simultaneously. Key drivers include public health priorities around sustained suppression and sustained prevention, patient demand for improved quality of life and discretion, and payer interest in avoiding lapses that lead to complications and onward transmission; on the industry side, maturation of formulation platforms, sterile manufacturing capabilities, and increasingly standardized service delivery all support uptake. Major barriers include access limitations inherent to facility-based administration, operational burdens from cold-chain and inventory requirements, management of injection-site reactions and long-term tolerability, and the resistance and transmission risks associated with interruption during the drug “tail,” which necessitate disciplined screening, follow-up, and contingency plans. Regional variation in regulation, procurement, and reimbursement can further slow penetration, while stigma, information gaps, and suboptimal service experiences may undermine persistence. As a result, competitive advantage will increasingly hinge not only on the molecule, but on end-to-end capabilities across screening, dosing, follow-up, supply assurance, and risk management.
This report is a detailed and comprehensive analysis for global Long-acting Anti-HIV Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Long-acting Anti-HIV Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting Anti-HIV Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting Anti-HIV Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting Anti-HIV Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-acting Anti-HIV Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-acting Anti-HIV Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ViiV Healthcare, Janssen Pharmaceuticals, Gilead Sciences, Theratechnologies, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Long-acting Anti-HIV Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Single Drug
- Combination Preparation
- Short-interval Injections
- Monthly Injections
- Quarterly Injections
- Original Drug
- Generic Drug
- Hospital
- Clinic
- Other
- ViiV Healthcare
- Janssen Pharmaceuticals
- Gilead Sciences
- Theratechnologies
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Long-acting Anti-HIV Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-acting Anti-HIV Drugs, with price, sales quantity, revenue, and global market share of Long-acting Anti-HIV Drugs from 2021 to 2026.
Chapter 3, the Long-acting Anti-HIV Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-acting Anti-HIV Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Long-acting Anti-HIV Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting Anti-HIV Drugs.
Chapter 14 and 15, to describe Long-acting Anti-HIV Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Injectable HIV Treatment Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Cabotegravir
1.3.3 Rilpivirine
1.3.4 Lenacapavir
1.3.5 Ibalizumab
1.3.6 Other
1.4 Market Analysis by Dosing Interval
1.4.1 Overview: Global Injectable HIV Treatment Consumption Value by Dosing Interval: 2021 Versus 2025 Versus 2032
1.4.2 Short-interval Injections
1.4.3 Monthly Injections
1.4.4 Quarterly Injections
1.5 Market Analysis by Drug Properties
1.5.1 Overview: Global Injectable HIV Treatment Consumption Value by Drug Properties: 2021 Versus 2025 Versus 2032
1.5.2 Original Drug
1.5.3 Generic Drug
1.6 Market Analysis by Application
1.6.1 Overview: Global Injectable HIV Treatment Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Pre-Exposure Prophylaxis
1.6.3 HIV Treatment
1.7 Global Injectable HIV Treatment Market Size & Forecast
1.7.1 Global Injectable HIV Treatment Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Injectable HIV Treatment Sales Quantity (2021-2032)
1.7.3 Global Injectable HIV Treatment Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 ViiV Healthcare
2.1.1 ViiV Healthcare Details
2.1.2 ViiV Healthcare Major Business
2.1.3 ViiV Healthcare Injectable HIV Treatment Product and Services
2.1.4 ViiV Healthcare Injectable HIV Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 ViiV Healthcare Recent Developments/Updates
2.2 Janssen Pharmaceuticals
2.2.1 Janssen Pharmaceuticals Details
2.2.2 Janssen Pharmaceuticals Major Business
2.2.3 Janssen Pharmaceuticals Injectable HIV Treatment Product and Services
2.2.4 Janssen Pharmaceuticals Injectable HIV Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Janssen Pharmaceuticals Recent Developments/Updates
2.3 Gilead Sciences
2.3.1 Gilead Sciences Details
2.3.2 Gilead Sciences Major Business
2.3.3 Gilead Sciences Injectable HIV Treatment Product and Services
2.3.4 Gilead Sciences Injectable HIV Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Gilead Sciences Recent Developments/Updates
2.4 Theratechnologies
2.4.1 Theratechnologies Details
2.4.2 Theratechnologies Major Business
2.4.3 Theratechnologies Injectable HIV Treatment Product and Services
2.4.4 Theratechnologies Injectable HIV Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Theratechnologies Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INJECTABLE HIV TREATMENT BY MANUFACTURER
3.1 Global Injectable HIV Treatment Sales Quantity by Manufacturer (2021-2026)
3.2 Global Injectable HIV Treatment Revenue by Manufacturer (2021-2026)
3.3 Global Injectable HIV Treatment Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Injectable HIV Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Injectable HIV Treatment Manufacturer Market Share in 2025
3.4.3 Top 6 Injectable HIV Treatment Manufacturer Market Share in 2025
3.5 Injectable HIV Treatment Market: Overall Company Footprint Analysis
3.5.1 Injectable HIV Treatment Market: Region Footprint
3.5.2 Injectable HIV Treatment Market: Company Product Type Footprint
3.5.3 Injectable HIV Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Injectable HIV Treatment Market Size by Region
4.1.1 Global Injectable HIV Treatment Sales Quantity by Region (2021-2032)
4.1.2 Global Injectable HIV Treatment Consumption Value by Region (2021-2032)
4.1.3 Global Injectable HIV Treatment Average Price by Region (2021-2032)
4.2 North America Injectable HIV Treatment Consumption Value (2021-2032)
4.3 Europe Injectable HIV Treatment Consumption Value (2021-2032)
4.4 Asia-Pacific Injectable HIV Treatment Consumption Value (2021-2032)
4.5 South America Injectable HIV Treatment Consumption Value (2021-2032)
4.6 Middle East & Africa Injectable HIV Treatment Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Injectable HIV Treatment Sales Quantity by Type (2021-2032)
5.2 Global Injectable HIV Treatment Consumption Value by Type (2021-2032)
5.3 Global Injectable HIV Treatment Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Injectable HIV Treatment Sales Quantity by Application (2021-2032)
6.2 Global Injectable HIV Treatment Consumption Value by Application (2021-2032)
6.3 Global Injectable HIV Treatment Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Injectable HIV Treatment Sales Quantity by Type (2021-2032)
7.2 North America Injectable HIV Treatment Sales Quantity by Application (2021-2032)
7.3 North America Injectable HIV Treatment Market Size by Country
7.3.1 North America Injectable HIV Treatment Sales Quantity by Country (2021-2032)
7.3.2 North America Injectable HIV Treatment Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Injectable HIV Treatment Sales Quantity by Type (2021-2032)
8.2 Europe Injectable HIV Treatment Sales Quantity by Application (2021-2032)
8.3 Europe Injectable HIV Treatment Market Size by Country
8.3.1 Europe Injectable HIV Treatment Sales Quantity by Country (2021-2032)
8.3.2 Europe Injectable HIV Treatment Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Injectable HIV Treatment Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Injectable HIV Treatment Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Injectable HIV Treatment Market Size by Region
9.3.1 Asia-Pacific Injectable HIV Treatment Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Injectable HIV Treatment Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Injectable HIV Treatment Sales Quantity by Type (2021-2032)
10.2 South America Injectable HIV Treatment Sales Quantity by Application (2021-2032)
10.3 South America Injectable HIV Treatment Market Size by Country
10.3.1 South America Injectable HIV Treatment Sales Quantity by Country (2021-2032)
10.3.2 South America Injectable HIV Treatment Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Injectable HIV Treatment Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Injectable HIV Treatment Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Injectable HIV Treatment Market Size by Country
11.3.1 Middle East & Africa Injectable HIV Treatment Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Injectable HIV Treatment Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Injectable HIV Treatment Market Drivers
12.2 Injectable HIV Treatment Market Restraints
12.3 Injectable HIV Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Injectable HIV Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Injectable HIV Treatment
13.3 Injectable HIV Treatment Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Injectable HIV Treatment Typical Distributors
14.3 Injectable HIV Treatment Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Injectable HIV Treatment Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Cabotegravir
1.3.3 Rilpivirine
1.3.4 Lenacapavir
1.3.5 Ibalizumab
1.3.6 Other
1.4 Market Analysis by Dosing Interval
1.4.1 Overview: Global Injectable HIV Treatment Consumption Value by Dosing Interval: 2021 Versus 2025 Versus 2032
1.4.2 Short-interval Injections
1.4.3 Monthly Injections
1.4.4 Quarterly Injections
1.5 Market Analysis by Drug Properties
1.5.1 Overview: Global Injectable HIV Treatment Consumption Value by Drug Properties: 2021 Versus 2025 Versus 2032
1.5.2 Original Drug
1.5.3 Generic Drug
1.6 Market Analysis by Application
1.6.1 Overview: Global Injectable HIV Treatment Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Pre-Exposure Prophylaxis
1.6.3 HIV Treatment
1.7 Global Injectable HIV Treatment Market Size & Forecast
1.7.1 Global Injectable HIV Treatment Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Injectable HIV Treatment Sales Quantity (2021-2032)
1.7.3 Global Injectable HIV Treatment Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 ViiV Healthcare
2.1.1 ViiV Healthcare Details
2.1.2 ViiV Healthcare Major Business
2.1.3 ViiV Healthcare Injectable HIV Treatment Product and Services
2.1.4 ViiV Healthcare Injectable HIV Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 ViiV Healthcare Recent Developments/Updates
2.2 Janssen Pharmaceuticals
2.2.1 Janssen Pharmaceuticals Details
2.2.2 Janssen Pharmaceuticals Major Business
2.2.3 Janssen Pharmaceuticals Injectable HIV Treatment Product and Services
2.2.4 Janssen Pharmaceuticals Injectable HIV Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Janssen Pharmaceuticals Recent Developments/Updates
2.3 Gilead Sciences
2.3.1 Gilead Sciences Details
2.3.2 Gilead Sciences Major Business
2.3.3 Gilead Sciences Injectable HIV Treatment Product and Services
2.3.4 Gilead Sciences Injectable HIV Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Gilead Sciences Recent Developments/Updates
2.4 Theratechnologies
2.4.1 Theratechnologies Details
2.4.2 Theratechnologies Major Business
2.4.3 Theratechnologies Injectable HIV Treatment Product and Services
2.4.4 Theratechnologies Injectable HIV Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Theratechnologies Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INJECTABLE HIV TREATMENT BY MANUFACTURER
3.1 Global Injectable HIV Treatment Sales Quantity by Manufacturer (2021-2026)
3.2 Global Injectable HIV Treatment Revenue by Manufacturer (2021-2026)
3.3 Global Injectable HIV Treatment Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Injectable HIV Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Injectable HIV Treatment Manufacturer Market Share in 2025
3.4.3 Top 6 Injectable HIV Treatment Manufacturer Market Share in 2025
3.5 Injectable HIV Treatment Market: Overall Company Footprint Analysis
3.5.1 Injectable HIV Treatment Market: Region Footprint
3.5.2 Injectable HIV Treatment Market: Company Product Type Footprint
3.5.3 Injectable HIV Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Injectable HIV Treatment Market Size by Region
4.1.1 Global Injectable HIV Treatment Sales Quantity by Region (2021-2032)
4.1.2 Global Injectable HIV Treatment Consumption Value by Region (2021-2032)
4.1.3 Global Injectable HIV Treatment Average Price by Region (2021-2032)
4.2 North America Injectable HIV Treatment Consumption Value (2021-2032)
4.3 Europe Injectable HIV Treatment Consumption Value (2021-2032)
4.4 Asia-Pacific Injectable HIV Treatment Consumption Value (2021-2032)
4.5 South America Injectable HIV Treatment Consumption Value (2021-2032)
4.6 Middle East & Africa Injectable HIV Treatment Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Injectable HIV Treatment Sales Quantity by Type (2021-2032)
5.2 Global Injectable HIV Treatment Consumption Value by Type (2021-2032)
5.3 Global Injectable HIV Treatment Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Injectable HIV Treatment Sales Quantity by Application (2021-2032)
6.2 Global Injectable HIV Treatment Consumption Value by Application (2021-2032)
6.3 Global Injectable HIV Treatment Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Injectable HIV Treatment Sales Quantity by Type (2021-2032)
7.2 North America Injectable HIV Treatment Sales Quantity by Application (2021-2032)
7.3 North America Injectable HIV Treatment Market Size by Country
7.3.1 North America Injectable HIV Treatment Sales Quantity by Country (2021-2032)
7.3.2 North America Injectable HIV Treatment Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Injectable HIV Treatment Sales Quantity by Type (2021-2032)
8.2 Europe Injectable HIV Treatment Sales Quantity by Application (2021-2032)
8.3 Europe Injectable HIV Treatment Market Size by Country
8.3.1 Europe Injectable HIV Treatment Sales Quantity by Country (2021-2032)
8.3.2 Europe Injectable HIV Treatment Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Injectable HIV Treatment Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Injectable HIV Treatment Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Injectable HIV Treatment Market Size by Region
9.3.1 Asia-Pacific Injectable HIV Treatment Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Injectable HIV Treatment Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Injectable HIV Treatment Sales Quantity by Type (2021-2032)
10.2 South America Injectable HIV Treatment Sales Quantity by Application (2021-2032)
10.3 South America Injectable HIV Treatment Market Size by Country
10.3.1 South America Injectable HIV Treatment Sales Quantity by Country (2021-2032)
10.3.2 South America Injectable HIV Treatment Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Injectable HIV Treatment Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Injectable HIV Treatment Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Injectable HIV Treatment Market Size by Country
11.3.1 Middle East & Africa Injectable HIV Treatment Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Injectable HIV Treatment Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Injectable HIV Treatment Market Drivers
12.2 Injectable HIV Treatment Market Restraints
12.3 Injectable HIV Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Injectable HIV Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Injectable HIV Treatment
13.3 Injectable HIV Treatment Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Injectable HIV Treatment Typical Distributors
14.3 Injectable HIV Treatment Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Long-acting Anti-HIV Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Long-acting Anti-HIV Drugs Consumption Value by Dosing Interval, (USD Million), 2021 & 2025 & 2032
Table 3. Global Long-acting Anti-HIV Drugs Consumption Value by Drug Properties, (USD Million), 2021 & 2025 & 2032
Table 4. Global Long-acting Anti-HIV Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. ViiV Healthcare Basic Information, Manufacturing Base and Competitors
Table 6. ViiV Healthcare Major Business
Table 7. ViiV Healthcare Long-acting Anti-HIV Drugs Product and Services
Table 8. ViiV Healthcare Long-acting Anti-HIV Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. ViiV Healthcare Recent Developments/Updates
Table 10. Janssen Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 11. Janssen Pharmaceuticals Major Business
Table 12. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product and Services
Table 13. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Janssen Pharmaceuticals Recent Developments/Updates
Table 15. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 16. Gilead Sciences Major Business
Table 17. Gilead Sciences Long-acting Anti-HIV Drugs Product and Services
Table 18. Gilead Sciences Long-acting Anti-HIV Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Gilead Sciences Recent Developments/Updates
Table 20. Theratechnologies Basic Information, Manufacturing Base and Competitors
Table 21. Theratechnologies Major Business
Table 22. Theratechnologies Long-acting Anti-HIV Drugs Product and Services
Table 23. Theratechnologies Long-acting Anti-HIV Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Theratechnologies Recent Developments/Updates
Table 25. Global Long-acting Anti-HIV Drugs Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 26. Global Long-acting Anti-HIV Drugs Revenue by Manufacturer (2021-2026) & (USD Million)
Table 27. Global Long-acting Anti-HIV Drugs Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 28. Market Position of Manufacturers in Long-acting Anti-HIV Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 29. Head Office and Long-acting Anti-HIV Drugs Production Site of Key Manufacturer
Table 30. Long-acting Anti-HIV Drugs Market: Company Product Type Footprint
Table 31. Long-acting Anti-HIV Drugs Market: Company Product Application Footprint
Table 32. Long-acting Anti-HIV Drugs New Market Entrants and Barriers to Market Entry
Table 33. Long-acting Anti-HIV Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 34. Global Long-acting Anti-HIV Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 35. Global Long-acting Anti-HIV Drugs Sales Quantity by Region (2021-2026) & (K Dose)
Table 36. Global Long-acting Anti-HIV Drugs Sales Quantity by Region (2027-2032) & (K Dose)
Table 37. Global Long-acting Anti-HIV Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 38. Global Long-acting Anti-HIV Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 39. Global Long-acting Anti-HIV Drugs Average Price by Region (2021-2026) & (US$/Dose)
Table 40. Global Long-acting Anti-HIV Drugs Average Price by Region (2027-2032) & (US$/Dose)
Table 41. Global Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 42. Global Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 43. Global Long-acting Anti-HIV Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 44. Global Long-acting Anti-HIV Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 45. Global Long-acting Anti-HIV Drugs Average Price by Type (2021-2026) & (US$/Dose)
Table 46. Global Long-acting Anti-HIV Drugs Average Price by Type (2027-2032) & (US$/Dose)
Table 47. Global Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 48. Global Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 49. Global Long-acting Anti-HIV Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 50. Global Long-acting Anti-HIV Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 51. Global Long-acting Anti-HIV Drugs Average Price by Application (2021-2026) & (US$/Dose)
Table 52. Global Long-acting Anti-HIV Drugs Average Price by Application (2027-2032) & (US$/Dose)
Table 53. North America Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 54. North America Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 55. North America Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 56. North America Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 57. North America Long-acting Anti-HIV Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 58. North America Long-acting Anti-HIV Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 59. North America Long-acting Anti-HIV Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 60. North America Long-acting Anti-HIV Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 61. Europe Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 62. Europe Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 63. Europe Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 64. Europe Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 65. Europe Long-acting Anti-HIV Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 66. Europe Long-acting Anti-HIV Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 67. Europe Long-acting Anti-HIV Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 68. Europe Long-acting Anti-HIV Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 69. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 70. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 71. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 72. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 73. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Region (2021-2026) & (K Dose)
Table 74. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Region (2027-2032) & (K Dose)
Table 75. Asia-Pacific Long-acting Anti-HIV Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 76. Asia-Pacific Long-acting Anti-HIV Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 77. South America Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 78. South America Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 79. South America Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 80. South America Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 81. South America Long-acting Anti-HIV Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 82. South America Long-acting Anti-HIV Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 83. South America Long-acting Anti-HIV Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 84. South America Long-acting Anti-HIV Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 85. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 86. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 87. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 88. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 89. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 90. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 91. Middle East & Africa Long-acting Anti-HIV Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 92. Middle East & Africa Long-acting Anti-HIV Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 93. Long-acting Anti-HIV Drugs Raw Material
Table 94. Key Manufacturers of Long-acting Anti-HIV Drugs Raw Materials
Table 95. Long-acting Anti-HIV Drugs Typical Distributors
Table 96. Long-acting Anti-HIV Drugs Typical Customers
Table 1. Global Long-acting Anti-HIV Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Long-acting Anti-HIV Drugs Consumption Value by Dosing Interval, (USD Million), 2021 & 2025 & 2032
Table 3. Global Long-acting Anti-HIV Drugs Consumption Value by Drug Properties, (USD Million), 2021 & 2025 & 2032
Table 4. Global Long-acting Anti-HIV Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. ViiV Healthcare Basic Information, Manufacturing Base and Competitors
Table 6. ViiV Healthcare Major Business
Table 7. ViiV Healthcare Long-acting Anti-HIV Drugs Product and Services
Table 8. ViiV Healthcare Long-acting Anti-HIV Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. ViiV Healthcare Recent Developments/Updates
Table 10. Janssen Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 11. Janssen Pharmaceuticals Major Business
Table 12. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product and Services
Table 13. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Janssen Pharmaceuticals Recent Developments/Updates
Table 15. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 16. Gilead Sciences Major Business
Table 17. Gilead Sciences Long-acting Anti-HIV Drugs Product and Services
Table 18. Gilead Sciences Long-acting Anti-HIV Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Gilead Sciences Recent Developments/Updates
Table 20. Theratechnologies Basic Information, Manufacturing Base and Competitors
Table 21. Theratechnologies Major Business
Table 22. Theratechnologies Long-acting Anti-HIV Drugs Product and Services
Table 23. Theratechnologies Long-acting Anti-HIV Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Theratechnologies Recent Developments/Updates
Table 25. Global Long-acting Anti-HIV Drugs Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 26. Global Long-acting Anti-HIV Drugs Revenue by Manufacturer (2021-2026) & (USD Million)
Table 27. Global Long-acting Anti-HIV Drugs Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 28. Market Position of Manufacturers in Long-acting Anti-HIV Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 29. Head Office and Long-acting Anti-HIV Drugs Production Site of Key Manufacturer
Table 30. Long-acting Anti-HIV Drugs Market: Company Product Type Footprint
Table 31. Long-acting Anti-HIV Drugs Market: Company Product Application Footprint
Table 32. Long-acting Anti-HIV Drugs New Market Entrants and Barriers to Market Entry
Table 33. Long-acting Anti-HIV Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 34. Global Long-acting Anti-HIV Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 35. Global Long-acting Anti-HIV Drugs Sales Quantity by Region (2021-2026) & (K Dose)
Table 36. Global Long-acting Anti-HIV Drugs Sales Quantity by Region (2027-2032) & (K Dose)
Table 37. Global Long-acting Anti-HIV Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 38. Global Long-acting Anti-HIV Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 39. Global Long-acting Anti-HIV Drugs Average Price by Region (2021-2026) & (US$/Dose)
Table 40. Global Long-acting Anti-HIV Drugs Average Price by Region (2027-2032) & (US$/Dose)
Table 41. Global Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 42. Global Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 43. Global Long-acting Anti-HIV Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 44. Global Long-acting Anti-HIV Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 45. Global Long-acting Anti-HIV Drugs Average Price by Type (2021-2026) & (US$/Dose)
Table 46. Global Long-acting Anti-HIV Drugs Average Price by Type (2027-2032) & (US$/Dose)
Table 47. Global Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 48. Global Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 49. Global Long-acting Anti-HIV Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 50. Global Long-acting Anti-HIV Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 51. Global Long-acting Anti-HIV Drugs Average Price by Application (2021-2026) & (US$/Dose)
Table 52. Global Long-acting Anti-HIV Drugs Average Price by Application (2027-2032) & (US$/Dose)
Table 53. North America Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 54. North America Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 55. North America Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 56. North America Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 57. North America Long-acting Anti-HIV Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 58. North America Long-acting Anti-HIV Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 59. North America Long-acting Anti-HIV Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 60. North America Long-acting Anti-HIV Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 61. Europe Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 62. Europe Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 63. Europe Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 64. Europe Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 65. Europe Long-acting Anti-HIV Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 66. Europe Long-acting Anti-HIV Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 67. Europe Long-acting Anti-HIV Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 68. Europe Long-acting Anti-HIV Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 69. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 70. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 71. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 72. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 73. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Region (2021-2026) & (K Dose)
Table 74. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity by Region (2027-2032) & (K Dose)
Table 75. Asia-Pacific Long-acting Anti-HIV Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 76. Asia-Pacific Long-acting Anti-HIV Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 77. South America Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 78. South America Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 79. South America Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 80. South America Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 81. South America Long-acting Anti-HIV Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 82. South America Long-acting Anti-HIV Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 83. South America Long-acting Anti-HIV Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 84. South America Long-acting Anti-HIV Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 85. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 86. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 87. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 88. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 89. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 90. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 91. Middle East & Africa Long-acting Anti-HIV Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 92. Middle East & Africa Long-acting Anti-HIV Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 93. Long-acting Anti-HIV Drugs Raw Material
Table 94. Key Manufacturers of Long-acting Anti-HIV Drugs Raw Materials
Table 95. Long-acting Anti-HIV Drugs Typical Distributors
Table 96. Long-acting Anti-HIV Drugs Typical Customers
LIST OF FIGURES
Figure 1. Long-acting Anti-HIV Drugs Picture
Figure 2. Global Long-acting Anti-HIV Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type in 2025
Figure 4. Single Drug Examples
Figure 5. Combination Preparation Examples
Figure 6. Global Long-acting Anti-HIV Drugs Revenue by Dosing Interval, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Long-acting Anti-HIV Drugs Revenue Market Share by Dosing Interval in 2025
Figure 8. Short-interval Injections Examples
Figure 9. Monthly Injections Examples
Figure 10. Quarterly Injections Examples
Figure 11. Global Long-acting Anti-HIV Drugs Revenue by Drug Properties, (USD Million), 2021 & 2025 & 2032
Figure 12. Global Long-acting Anti-HIV Drugs Revenue Market Share by Drug Properties in 2025
Figure 13. Original Drug Examples
Figure 14. Generic Drug Examples
Figure 15. Global Long-acting Anti-HIV Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 16. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application in 2025
Figure 17. Hospital Examples
Figure 18. Clinic Examples
Figure 19. Other Examples
Figure 20. Global Long-acting Anti-HIV Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 21. Global Long-acting Anti-HIV Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 22. Global Long-acting Anti-HIV Drugs Sales Quantity (2021-2032) & (K Dose)
Figure 23. Global Long-acting Anti-HIV Drugs Price (2021-2032) & (US$/Dose)
Figure 24. Global Long-acting Anti-HIV Drugs Sales Quantity Market Share by Manufacturer in 2025
Figure 25. Global Long-acting Anti-HIV Drugs Revenue Market Share by Manufacturer in 2025
Figure 26. Producer Shipments of Long-acting Anti-HIV Drugs by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 27. Top 3 Long-acting Anti-HIV Drugs Manufacturer (Revenue) Market Share in 2025
Figure 28. Top 6 Long-acting Anti-HIV Drugs Manufacturer (Revenue) Market Share in 2025
Figure 29. Global Long-acting Anti-HIV Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 30. Global Long-acting Anti-HIV Drugs Consumption Value Market Share by Region (2021-2032)
Figure 31. North America Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 32. Europe Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 33. Asia-Pacific Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 34. South America Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 35. Middle East & Africa Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 36. Global Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 37. Global Long-acting Anti-HIV Drugs Consumption Value Market Share by Type (2021-2032)
Figure 38. Global Long-acting Anti-HIV Drugs Average Price by Type (2021-2032) & (US$/Dose)
Figure 39. Global Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 40. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2021-2032)
Figure 41. Global Long-acting Anti-HIV Drugs Average Price by Application (2021-2032) & (US$/Dose)
Figure 42. North America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 43. North America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 44. North America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 45. North America Long-acting Anti-HIV Drugs Consumption Value Market Share by Country (2021-2032)
Figure 46. United States Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 47. Canada Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 48. Mexico Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. Europe Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 50. Europe Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 51. Europe Long-acting Anti-HIV Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 52. Europe Long-acting Anti-HIV Drugs Consumption Value Market Share by Country (2021-2032)
Figure 53. Germany Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 54. France Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 55. United Kingdom Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 56. Russia Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 57. Italy Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 59. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 60. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 61. Asia-Pacific Long-acting Anti-HIV Drugs Consumption Value Market Share by Region (2021-2032)
Figure 62. China Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. Japan Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. South Korea Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 65. India Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 66. Southeast Asia Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 67. Australia Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. South America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 69. South America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 70. South America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 71. South America Long-acting Anti-HIV Drugs Consumption Value Market Share by Country (2021-2032)
Figure 72. Brazil Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 73. Argentina Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 74. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 75. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 76. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 77. Middle East & Africa Long-acting Anti-HIV Drugs Consumption Value Market Share by Country (2021-2032)
Figure 78. Turkey Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 79. Egypt Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 80. Saudi Arabia Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 81. South Africa Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 82. Long-acting Anti-HIV Drugs Market Drivers
Figure 83. Long-acting Anti-HIV Drugs Market Restraints
Figure 84. Long-acting Anti-HIV Drugs Market Trends
Figure 85. Porters Five Forces Analysis
Figure 86. Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drugs in 2025
Figure 87. Manufacturing Process Analysis of Long-acting Anti-HIV Drugs
Figure 88. Long-acting Anti-HIV Drugs Industrial Chain
Figure 89. Sales Channel: Direct to End-User vs Distributors
Figure 90. Direct Channel Pros & Cons
Figure 91. Indirect Channel Pros & Cons
Figure 92. Methodology
Figure 93. Research Process and Data Source
Figure 1. Long-acting Anti-HIV Drugs Picture
Figure 2. Global Long-acting Anti-HIV Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type in 2025
Figure 4. Single Drug Examples
Figure 5. Combination Preparation Examples
Figure 6. Global Long-acting Anti-HIV Drugs Revenue by Dosing Interval, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Long-acting Anti-HIV Drugs Revenue Market Share by Dosing Interval in 2025
Figure 8. Short-interval Injections Examples
Figure 9. Monthly Injections Examples
Figure 10. Quarterly Injections Examples
Figure 11. Global Long-acting Anti-HIV Drugs Revenue by Drug Properties, (USD Million), 2021 & 2025 & 2032
Figure 12. Global Long-acting Anti-HIV Drugs Revenue Market Share by Drug Properties in 2025
Figure 13. Original Drug Examples
Figure 14. Generic Drug Examples
Figure 15. Global Long-acting Anti-HIV Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 16. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application in 2025
Figure 17. Hospital Examples
Figure 18. Clinic Examples
Figure 19. Other Examples
Figure 20. Global Long-acting Anti-HIV Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 21. Global Long-acting Anti-HIV Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 22. Global Long-acting Anti-HIV Drugs Sales Quantity (2021-2032) & (K Dose)
Figure 23. Global Long-acting Anti-HIV Drugs Price (2021-2032) & (US$/Dose)
Figure 24. Global Long-acting Anti-HIV Drugs Sales Quantity Market Share by Manufacturer in 2025
Figure 25. Global Long-acting Anti-HIV Drugs Revenue Market Share by Manufacturer in 2025
Figure 26. Producer Shipments of Long-acting Anti-HIV Drugs by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 27. Top 3 Long-acting Anti-HIV Drugs Manufacturer (Revenue) Market Share in 2025
Figure 28. Top 6 Long-acting Anti-HIV Drugs Manufacturer (Revenue) Market Share in 2025
Figure 29. Global Long-acting Anti-HIV Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 30. Global Long-acting Anti-HIV Drugs Consumption Value Market Share by Region (2021-2032)
Figure 31. North America Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 32. Europe Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 33. Asia-Pacific Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 34. South America Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 35. Middle East & Africa Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 36. Global Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 37. Global Long-acting Anti-HIV Drugs Consumption Value Market Share by Type (2021-2032)
Figure 38. Global Long-acting Anti-HIV Drugs Average Price by Type (2021-2032) & (US$/Dose)
Figure 39. Global Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 40. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2021-2032)
Figure 41. Global Long-acting Anti-HIV Drugs Average Price by Application (2021-2032) & (US$/Dose)
Figure 42. North America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 43. North America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 44. North America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 45. North America Long-acting Anti-HIV Drugs Consumption Value Market Share by Country (2021-2032)
Figure 46. United States Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 47. Canada Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 48. Mexico Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. Europe Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 50. Europe Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 51. Europe Long-acting Anti-HIV Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 52. Europe Long-acting Anti-HIV Drugs Consumption Value Market Share by Country (2021-2032)
Figure 53. Germany Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 54. France Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 55. United Kingdom Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 56. Russia Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 57. Italy Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 59. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 60. Asia-Pacific Long-acting Anti-HIV Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 61. Asia-Pacific Long-acting Anti-HIV Drugs Consumption Value Market Share by Region (2021-2032)
Figure 62. China Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. Japan Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. South Korea Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 65. India Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 66. Southeast Asia Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 67. Australia Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. South America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 69. South America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 70. South America Long-acting Anti-HIV Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 71. South America Long-acting Anti-HIV Drugs Consumption Value Market Share by Country (2021-2032)
Figure 72. Brazil Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 73. Argentina Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 74. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 75. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 76. Middle East & Africa Long-acting Anti-HIV Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 77. Middle East & Africa Long-acting Anti-HIV Drugs Consumption Value Market Share by Country (2021-2032)
Figure 78. Turkey Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 79. Egypt Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 80. Saudi Arabia Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 81. South Africa Long-acting Anti-HIV Drugs Consumption Value (2021-2032) & (USD Million)
Figure 82. Long-acting Anti-HIV Drugs Market Drivers
Figure 83. Long-acting Anti-HIV Drugs Market Restraints
Figure 84. Long-acting Anti-HIV Drugs Market Trends
Figure 85. Porters Five Forces Analysis
Figure 86. Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drugs in 2025
Figure 87. Manufacturing Process Analysis of Long-acting Anti-HIV Drugs
Figure 88. Long-acting Anti-HIV Drugs Industrial Chain
Figure 89. Sales Channel: Direct to End-User vs Distributors
Figure 90. Direct Channel Pros & Cons
Figure 91. Indirect Channel Pros & Cons
Figure 92. Methodology
Figure 93. Research Process and Data Source
